Literature DB >> 7509751

Blockade of tachykinin NK1 receptors by CP-96345 enhances dopamine release and the striatal dopamine effects of methamphetamine in rats.

S P Gygi1, J W Gibb, M Johnson, G R Hanson.   

Abstract

The nonpeptide, tachykinin NK1 receptor antagonist, CP-96345, permits the study of the physiological role of extrapyramidal substance P systems. Using microdialysis, we observed that locally applied CP-96345 (200 nM) caused a significant increase in dopamine release in the striatum as well as substantially enhancing striatal dopamine release caused by a low dose of methamphetamine (0.5 mg/kg s.c.). In addition, multiple systemic administrations of CP-96345 almost doubled the dopamine-mediated responses of the striatal neurotensin and dynorphin systems to high doses of methamphetamine (10 mg/kg/dose s.c.). Our findings suggest that the physiological role of substance P released in the striatum is to decrease the activity of the nigrostriatal dopamine pathway.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7509751     DOI: 10.1016/0014-2999(93)90639-y

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Histological evidence supporting a role for the striatal neurokinin-1 receptor in methamphetamine-induced neurotoxicity in the mouse brain.

Authors:  Jing Yu; Jing Wang; Jean Lud Cadet; Jesus A Angulo
Journal:  Brain Res       Date:  2004-05-08       Impact factor: 3.252

2.  Substance P Weights Striatal Dopamine Transmission Differently within the Striosome-Matrix Axis.

Authors:  Katherine R Brimblecombe; Stephanie J Cragg
Journal:  J Neurosci       Date:  2015-06-17       Impact factor: 6.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.